News
9d
Zacks Investment Research on MSNEli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...
2d
Zacks Investment Research on MSNHow Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...
Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...
Eli Lilly (LLY) shares rallied 14.3% in the last trading session to close at $839.96. ... Merck's consensus EPS estimate for the upcoming report has changed -4% over the past month to $2.16.
Though specifics of the order were not clear, shares of all large drugmakers, J&J, Eli Lilly, Pfizer, Merck, Gilead, Bristol-Myers, Amgen and several other U.S. pharmaceutical stocks were on the ...
Eli Lilly and Co. LLY fell 18% in May, its steepest monthly drop since February 2009. ... UnitedHealth Group is expected to rise by 18%, while Merck & Co. is forecasted 27% higher the next 12 months.
Eli Lilly's blockbuster diabetes treatment Mounjaro topped expectations for the first quarter, raking in $3.84 billion in revenue. That's up a whopping 113% from the same period a year ago.
Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). GLP-1 receptor agonist ...
Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year. The ...
A cautious culture cost Novo its obesity lead. Danish drugmaker Novo Nordisk was the first to sell a new generation of GLP-1 obesity drugs, but it’s now widely seen as trailing Eli Lilly.
Merck Animal Health and Kansas announced a $895 million investment in manufacturing as well as research and development facilities in De Soto. Eli Lilly is set to pay up to $415 million in an ALS ...
(Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results